TD-HV985016

Enfortumab(TD-HV985016) is a research-grade recombinant antibody targetingLNIR. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Human

IgG1-kappa

Monoclonal

LNIR, NECTIN4, PRR4 receptor-related protein 4, Nectin cell adhesion molecule 4, Ig superfamily receptor LNIR, Nectin-4, PVRL4

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q96NY8

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

AGS-22CE, AGS-22M, AGS-22M6E, unconjugated:AGS-22C3orAGSM6, 1448664-46-7

Enfortumab vedotin is an antibody-drug conjugate (ADC) designed for the treatment of cancer expressing Nectin-4. It was developed through two main lines, hybridoma (ASG-22ME) and Chinese hamster ovary (ASG-22CE). Enfortumab refers to the fully humanized (from mouse) monoclonal antibody (mAb) created by scientists at Agensys (part of Astellas) using Amgen’s transgenic system (XenoMouse), it is the first agent to target Nectin-4 that expressed on many solid tumors especially on bladder cancers. Vedotin refers to the payload drug microtubule-disrupting agent monomethyl auristatin E (MMAE) and the linker. The linker technology holding the antibody and the toxin together was provided by and licensed from Seattle Genetics. Preclinical studies showed that enfortumab vedotin effectively binds to target cells, internalizes and induces cell-killing activity. Mouse and patient xenograft models were used to test enfortumab vedotin’s antitumor activity in human breast, bladder, pancreatic and lung cancers. In March 2018, Seattle Genetics and Astellas received the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for enfortumab vedotin based on interim results from the phase 1 study examining enfortumab vedotin as monotherapy treatment for patients with metastatic urothelial cancer who were previously treated with checkpoint inhibitors.

SEC-HPLC detection for Research Grade Enfortumab.　　|　Detects NECTIN4/PVRL4 in indirect ELISAs.　　|　SDS-PAGE for Research Grade Enfortumab.　　|　Flow-cytometry using anti-human Nectin 4 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human Nectin 4 monoclonal antibody (Catalog: HV985016) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.　　|　Western blot analysis was performed using anti-NECTIN4 monoclonal antibody at 1ug/mL on various samples.Lane 1:recombinant human NECTIN4 (Catalog No:TD-HV985011)Lane 2:negative control

For research use only. Not suitable for clinical or therapeutic use.